Xie Chencheng, Abdullah Hafez Mohammad Ammar, Abdallah Mohamed, Quist Erin, Niazi Mumtaz
Internal Medicine, University of South Dakota Sanford School of Medicine, Sioux Falls, South Dakota, USA.
Internal Medicine, University of South Dakota Sanford School of Medicine, Sioux Falls, South Dakota, USA
BMJ Case Rep. 2019 Nov 27;12(11):e231741. doi: 10.1136/bcr-2019-231741.
Anastrozole is an aromatase inhibitor that has been used more frequently over the last decade especially for oestrogen receptor-positive breast cancer. It has a relatively safe side effect profile. However, occasionally it has been associated with serious adverse events. Here, we present the case of a 58-year-old woman who presented with significantly elevated liver enzymes 4 years after starting anastrozole. She was not taking any other medications and an extensive workup did not reveal any other cause for her liver injury. The patient's liver enzymes normalised after discounting the anastrozole. She scored 4 on the updated Roussel Uclaf Causality Assessment Method grading system which was possible for drug-induced liver injury. A review of the literature revealed six prior cases of anastrozole-related liver injury. Anastrozole should be considered as a possible culprit in patients who develop an unexplained acute liver injury.
阿那曲唑是一种芳香化酶抑制剂,在过去十年中使用频率越来越高,尤其用于雌激素受体阳性乳腺癌。它的副作用相对安全。然而,偶尔也会与严重不良事件相关。在此,我们报告一例58岁女性病例,该患者在开始使用阿那曲唑4年后出现肝酶显著升高。她未服用任何其他药物,广泛检查未发现其他导致其肝损伤的原因。停用阿那曲唑后,患者的肝酶恢复正常。在更新的鲁塞尔·乌克拉夫因果关系评估方法分级系统中,她的得分是4分,这在药物性肝损伤中是有可能的。文献回顾发现了6例先前与阿那曲唑相关的肝损伤病例。对于出现不明原因急性肝损伤的患者,应考虑阿那曲唑可能是病因。